NCT00039871View on ClinicalTrials.gov

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

PHASE3CompletedINTERVENTIONAL
Enrollment

2,333

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
HepatitisHepatitis C, ChronicFibrosisLiver Cirrhosis
Interventions
BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks

DRUG

REBETOL (ribavirin; SCH 18908)

REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00039871 - PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | Biotech Hunter | Biotech Hunter